Tumor necrosis factor α antagonists in the treatment of the patients with rheumatoid arthritis

Szeremeta, Anna; Olczyk, Krystyna

doi:10.5114/reum.2012.31407

Cited by 5 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, regarding the changes observed in our study, it can be concluded that anti-TNF therapy affects the genes associated with the TNF signal pathway by altering the expression of receptors for this cytokine. Moreover, the profile of changes in receptors expression depends on the type of anti-TNF drug and the observed TNFR1/TNFR2 ratio may result from a different structure and mechanism of action of adalimumab and etanercept [4,9,10,27]. However, given the fact that we noted a higher transcriptional activity of TNFR1 than TNFR2 in the control group, etanercept does not appear to be toxic.…”

Section: Discussionmentioning

confidence: 65%

“…The increase in TNF-α expression observed in the first monitorings after the inclusion of etanercept may result from the extension of the inflammatory process to peripheral joints. TNF-α stimulates the secretion of extracellular matrix metalloproteinases (MMPs), responsible for the remodelling of extracellular matrix of the articular cartilage, from infiltrating inflammatory cells [27]. In addition, previous reports confirming an elevated concentration of TNF-α during etanercept therapy associated with its long halflife in serum should be taken into account [28].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Wcisło‐Dziadecka¹,

Grabarek²,

Swinarew³

et al. 2020

pdia

View full text Add to dashboard Cite

Introduction: Adalimumab and etanercept are drugs used in anti-TNF therapy in patients with psoriasis and psoriatic arthritis. Despite the molecular targeting of these drugs, the loss of pharmacological response to treatment is observed in patients. The development of personalized medicine makes it possible to use not only clinical parameters of disease severity, but also molecular marker systems. Aim: The aim of the study was to evaluate the changes in TNF-α, TNFR1, and TNFR2 expression in relation to parameters of disease severity (PASI, BSA, DAS28) in patients treated with adalimumab and etanercept. We have attempted to determine whether changes in the TNF-α, TNFR1, and TNFR2 expression profile may be a useful molecular marker of the therapeutic potential of anti-TNF drugs. Material and methods:The study group consisted of 3 patients initially treated with adalimumab, followed by etanercept. The control group included 20 healthy volunteers. The expression profile of TNFR1 and TNFR2 was determined at the mRNA level, while TNF-α expression was evaluated at the transcriptome and proteome levels using the RT-qPCR method (transcriptional activity assay) and MALDI-TOF MS (protein level assessment). Results: Depending on the drug, different expression profiles of the studied cytokines are observed. Conclusions: The obtained data indicate that TNF-α, TNFR1, and TNFR2 may be useful markers of the efficacy of anti-TNF therapy, thus complementing clinical parameters.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Wcisło‐Dziadecka¹,

Grabarek²,

Swinarew³

et al. 2020

pdia

View full text Add to dashboard Cite

show abstract

“…Persisting relatively high level of cytokine expression when the drug was changed may explain the body compensation mechanism aiming at homeostasis. Or perhaps the lack of efficacy of the primary treatment was connected with an intensified TNF-α secretion that was not neutralized [17].…”

Section: Omówieniementioning

confidence: 99%

“…Utrzymujący się stosunkowo wysoki poziom ekspresji cytokiny przy zmianie leku można tłumaczyć mechanizmem kompensacyjnym organizmu i dążeniem do osiągnięcia homeostazy. Niewykluczone również, że brak skuteczności pierwotnego leczenia wiązał się z nasilającą się sekrecją TNF-α, który nie ulegał neutralizacji [17].…”

Section: Omówienieunclassified

Drug resistance in anti-TNF therapy of psoriatic arthritis

Wcisło‐Dziadecka¹,

Grabarek²,

Brzeźińska-Wcisło³

et al. 2018

View full text Add to dashboard Cite

Introduction. Despite of the molecular targeting anti-TNF therapy, drug resistance may be observed. A method of avoiding this phenomenon, changing treatment early and increasing its effectiveness, the new molecular markers may be used. Objective. To present clinical (PASI, BSA, DAS28, DLQI) and molecular (TNF-α, TNFR1, TNFR2) parameters of loss of efficacy to etanercept in a patient with psoriatic arthritis. Case report. Patient aged 64, initially treated with etanercept then adalimumab because of psoriatic arthritis. During the observation, the loss of response to the anti-TNF drug was observed. During subsequent visits, whole blood was collected from the patient for molecular analysis based on the RTqPCR. Conclusions. Molecular markers such as TNF-α, TNFR1, TNFR2 seem to be useful for early detection of drug resistance and fit into the model of personalised medicine. streszczenie Wprowadzenie. Terapia anty-TNF, mimo molekularnego ukierunkowania działania, wiąże się ze zjawiskiem lekooporności. Sposobem na odpowiednio wczesną zmianę leczenia i zwiększenie jego skuteczności jest zastosowanie nowych markerów molekularnych. Cel pracy. Przedstawienie klinicznych (PASI, BSA, DAS28, DLQI) i molekularnych (TNF-α, TNFR1, TNFR2) parametrów utraty skuteczności leczenia etanerceptem u pacjentki z łuszczycą stawową. Opis przypadku. Pacjentka, lat 64, początkowo leczona etanerceptem, następnie adalimumabem z powodu łuszczycy stawowej. Podczas obserwacji stwierdzono utratę odpowiedzi terapeutycznej na lek anty-TNF. W trakcie kolejnych wizyt pobierano od pacjentki krew pełną do analiz molekularnych z zastosowaniem metody RTqPCR.

show abstract

“…The introduction of biologic drugs which neutralize TNF-α activity was a breakthrough in RA treatment. The results of clinical trials revealed a significant reduction of disease activity and inhibition of radiological progression, as well as improvement in the quality of life and physical function in RA patients treated with TNF-α inhibitors (TNFαI) [ 16 – 18 ]. However, the effect of anti-TNF therapy on PG/GAG metabolism in RA is still unknown.…”

Section: Introductionmentioning

confidence: 99%

Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundIn this study, the effect of 15-month anti-tumor necrosis factor alpha (TNF-α) treatment on circulating levels of plasma sulfated glycosaminoglycans (GAGs) and the nonsulfated GAG hyaluronic acid (HA) in female rheumatoid arthritis (RA) patients was assessed.MethodsPlasma was obtained from healthy subjects and RA women treated with TNF-α antagonists (etanercept or adalimumab or certolizumab pegol) in combination with methotrexate. GAGs were isolated from plasma samples using ion exchange low-pressure liquid chromatography. Total sulfated GAGs were quantified using a hexuronic acid assay. Plasma levels of keratan sulfate (KS) and HA were measured using immunoassay kits.ResultsTotal sulfated GAGs and HA levels were higher in female RA patients before treatment in comparison to healthy subjects. KS levels did not differ between RA women and controls. Anti-TNF-α treatment resulted in normalization of plasma total GAG and HA levels in RA patients, without any effect on KS levels.ConclusionsOur results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.

show abstract

Tumor necrosis factor α antagonists in the treatment of the patients with rheumatoid arthritis

Cited by 5 publications

References 21 publications

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis

Drug resistance in anti-TNF therapy of psoriatic arthritis

Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis

Contact Info

Product

Resources

About